EstabilishingSOBI

Born from two Swedish companies (Biovitrum and Swedish Orphan International), SOBI’s success story is one of entrepreneurial innovation in the rare disease field. BlueDil founders were key contributors during these early growth years, supporting SOBI in achieving its strategic goals, establishing a leadership position in this specialized market and expanding its presence across Europe.

2006

Opening affiliates in United Kingdom, France and Germany

2007

Merger between Swedish Orphan International and Biovitrium

2010

Opening affiliates in Spain and Italy

Key Success Factors inherited at BlueDil International from SOBI experience

  • RARE DISEASE MINDSET

    • Tailored Approach: Recognizing that rare diseases demand a specialized strategy distinct from the blockbuster drugs market.
    • In-Depth Expertise: Extensive understanding of national rare disease landscapes and regulatory environments.

  • END-TO-END LIFECYCLE SOLUTIONS

    • Expertise in developing comprehensive operating models, that encompass Early Access Programs, Price & Reimbursement strategies, launch and post-launch activities across multiple therapeutic areas

  • LEAN AND EFFICIENT ORGANIZATION

    • Highly skilled small teams able to achieve strategic objectives, by streamlining processes and workflows and deliver high-impact result across all operations
    • High level of teamworking across European countries, ensuring smooth cross-border coordination

  • KEY STAKEHOLDERS ENGAGEMENT

    • Strong collaboration with key stakeholders at local and European level to understand the unmet needs, raise disease awareness, refine scientific and clinical development, ensuring patients an early access to their orphan therapies.

  • STRATEGY & OPERATIONAL CAPABILITIES

    • Selection of teams with a blend of strategic vision and operational capabilities to combine long-term planning with effective local implementation, able to deliver sustainable and impactful results, and adapt to evolving needs and opportunities.

  • ADAPTIVE AGILITY & RESOURCE OPTIMIZATION

    • Seamless agile approach maximized the ability to achieve strategic objectives with optimization of available resources.

Success stories from our
Senior Leaders’ SOBI experience

Therapeutic Area Rare Disease Orphan Therapy
Metabolic diseases Urea cycle disorders Ammonaps, Ravicti, Ammonul Strong connections with the scientific community
Tyrosinemia Orfadin
Haematology Thalassemia Ferriprox Strategic alliances with leading pharma and biotech companies
Autoimmune diseases Still diseases and Rheumatoid arthritis Kineret Out of the box thinking
Oncology Advanced soft-tissue sarcoma and relapsed ovarian cancer Yondelis Important scientific programmes